A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
❓ Unknown
NAD-boosting treatment fails to show benefits for Parkinson's in major trial
3w ago
October 9, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A clinical trial involving 410 participants with early Parkinson's disease found that nicotinamide riboside (NR) showed no clinical benefits. The study, published in JAMA, raises questions about the efficacy of NAD-boosting treatments. This is relevant for Iran as it reflects ongoing global health research that may influence local medical practices and policies.
🔍 Quick Context Guide
💡 Bottom Line:
The failure of NR to show benefits in this trial raises questions about the future of NAD-boosting treatments for Parkinson's disease.
👥 Key Players
JAMA
MENTIONED
Medical Journal
"JAMA is a leading medical journal that publishes significant research findings, influencing medical practices globally, including in Iran."
Researchers involved in the trial
MENTIONED
Clinical researchers
"Their work contributes to the understanding of Parkinson's disease and potential treatments, impacting healthcare policies and practices."
📰 What Happened
A major clinical trial with 410 participants diagnosed with early Parkinson's disease found that nicotinamide riboside (NR) did not provide any clinical benefits. This raises concerns regarding the effectiveness of NAD-boosting treatments.
- The trial involved 410 participants with early-stage Parkinson's disease.
- The findings were published in the Journal of the American Medical Association (JAMA).
💡 Why It Matters
🇮🇷 For Iran: The results may affect how Iranian medical practitioners approach treatment options for Parkinson's disease, especially regarding NAD-boosting therapies.
🌍 Regional: The findings could influence regional research priorities and funding for neurodegenerative disease treatments.
🌐 International: This trial's results may lead to reevaluation of NAD-boosting treatments in other countries, impacting global health strategies.
📚 Background
Nicotinamide riboside (NR) is a compound thought to enhance cellular energy metabolism, and its potential benefits for neurodegenerative diseases like Parkinson's have been a subject of research. Understanding Parkinson's disease is crucial as it affects millions worldwide.
Parkinson's disease
Nicotinamide adenine dinucleotide (NAD)
Neurodegenerative diseases
📡 Source:
NEUTRAL
📊 Confidence:
70%
JAMA is a reputable source in the medical community, providing peer-reviewed research that is generally considered reliable.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Trump: Negotiations with Iran are progressing well but are not trustworthy
12 min ago •
New Gains for Iran from the U.S.; The Story of the Capture of Two MQM-170…
15 min ago •
US Accuses North Korea in $6.3 Billion Cyber Theft Case
24 min ago •
Reyhaneh, Mahsa, and 2 Incredible Events!
29 min ago •